Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study by Gurwith, Marc, Dr, Lock, Michael, PhD, Taylor, Eve M, PhD, Ishioka, Glenn, PhD, Alexander, Jeff, PhD, Mayall, Tim, PhD, Ervin, John E, MD, Greenberg, Richard N, Prof, Strout, Cynthia, MD, Treanor, John J, Prof, Webby, Richard, PhD, Wright, Peter F, Prof

Get full text